Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 214

1.

Prospective study of transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: an Asian cooperative study between Japan and Korea.

Ikeda M, Arai Y, Park SJ, Takeuchi Y, Anai H, Kim JK, Inaba Y, Aramaki T, Kwon SH, Yamamoto S, Okusaka T; Japan Interventional Radiology in Oncology Study Group (JIVROSG); Korea Interventional Radiology in Oncology Study Group (KIVROSG).

J Vasc Interv Radiol. 2013 Apr;24(4):490-500. doi: 10.1016/j.jvir.2013.01.003. Epub 2013 Mar 7.

PMID:
23466316
2.

Degradable starch microspheres versus ethiodol and doxorubicin in transarterial chemoembolization of hepatocellular carcinoma.

Niessen C, Unterpaintner E, Goessmann H, Schlitt HJ, Mueller-Schilling M, Wohlgemuth WA, Stroszczynski C, Wiggermann P.

J Vasc Interv Radiol. 2014 Feb;25(2):240-7. doi: 10.1016/j.jvir.2013.10.007. Epub 2013 Nov 28.

PMID:
24291001
3.

Clinical evaluation of transcatheter arterial chemoembolization with 2-day-soluble gelatin sponge particles for hepatocellular carcinoma-comparison with insoluble gelatin sponge particles.

Kawai N, Sato M, Minamiguchi H, Ikoma A, Sanda H, Nakata K, Sato H, Sakaguchi H, Nakai M, Sonomura T.

J Vasc Interv Radiol. 2013 Sep;24(9):1383-90. doi: 10.1016/j.jvir.2013.03.013. Epub 2013 May 30.

PMID:
23727419
4.

Transarterial chemoembolization with cisplatin as second-line treatment for hepatocellular carcinoma unresponsive to chemoembolization with epirubicin-Lipiodol emulsion.

Maeda N, Osuga K, Higashihara H, Tomoda K, Mikami K, Nakazawa T, Nakamura H, Tomiyama N.

Cardiovasc Intervent Radiol. 2012 Feb;35(1):82-9. doi: 10.1007/s00270-010-0086-6. Epub 2011 Jan 4.

PMID:
21203761
5.

Transcatheter arterial chemotherapy using miriplatin-lipiodol suspension with or without embolization for unresectable hepatocellular carcinoma.

Imai N, Ikeda K, Kawamura Y, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Saitoh S, Suzuki F, Suzuki Y, Arase Y, Kumada H.

Jpn J Clin Oncol. 2012 Mar;42(3):175-82. doi: 10.1093/jjco/hyr189. Epub 2011 Dec 30.

6.

Transcatheter arterial chemoembolization with doxorubicin-eluting superabsorbent polymer microspheres in the treatment of hepatocellular carcinoma: midterm follow-up.

Dekervel J, van Malenstein H, Vandecaveye V, Nevens F, van Pelt J, Heye S, Laleman W, Van Steenbergen W, Vaninbroukx J, Verslype C, Maleux G.

J Vasc Interv Radiol. 2014 Feb;25(2):248-55.e1. doi: 10.1016/j.jvir.2013.10.017. Epub 2013 Dec 2.

PMID:
24295569
7.

Single-step multimodal locoregional treatment for unresectable hepatocellular carcinoma: balloon-occluded percutaneous radiofrequency thermal ablation (BO-RFA) plus transcatheter arterial chemoembolization (TACE).

Iezzi R, Cesario V, Siciliani L, Campanale M, De Gaetano AM, Siciliano M, Agnes S, Giuliante F, Grieco A, Pompili M, Rapaccini GL, Gasbarrini A, Bonomo L; HepatoCATT Group for the Multidisciplinary Management of HCC.

Radiol Med. 2013 Jun;118(4):555-69. doi: 10.1007/s11547-012-0914-7. Epub 2013 Jan 28.

PMID:
23358819
8.

Treatment of hepatocellular carcinoma using doxorubicin/ethiodized oil/gelatin powder chemoembolization.

Stuart K, Stokes K, Jenkins R, Trey C, Clouse M.

Cancer. 1993 Dec 1;72(11):3202-9.

9.

Chemoembolization for hepatocellular carcinoma: epinephrine followed by a doxorubicin-ethiodized oil emulsion and gelatin sponge powder.

Clouse ME, Stokes KR, Kruskal JB, Perry LJ, Stuart KE, Nasser IA.

J Vasc Interv Radiol. 1993 Nov-Dec;4(6):717-25.

PMID:
7506597
10.

Safety and efficacy of doxorubicin drug-eluting bead transarterial chemoembolization in patients with advanced hepatocellular carcinoma.

Prajapati HJ, Dhanasekaran R, El-Rayes BF, Kauh JS, Maithel SK, Chen Z, Kim HS.

J Vasc Interv Radiol. 2013 Mar;24(3):307-15. doi: 10.1016/j.jvir.2012.11.026. Epub 2013 Jan 29.

PMID:
23375519
11.

Drug-eluting bead loaded with doxorubicin versus conventional Lipiodol-based transarterial chemoembolization in the treatment of hepatocellular carcinoma: a case-control study of Asian patients.

Song MJ, Park CH, Kim JD, Kim HY, Bae SH, Choi JY, Yoon SK, Chun HJ, Choi BG, Lee HG.

Eur J Gastroenterol Hepatol. 2011 Jun;23(6):521-7. doi: 10.1097/MEG.0b013e328346d505.

PMID:
21537127
12.

Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients.

Takayasu K, Arii S, Ikai I, Omata M, Okita K, Ichida T, Matsuyama Y, Nakanuma Y, Kojiro M, Makuuchi M, Yamaoka Y; Liver Cancer Study Group of Japan.

Gastroenterology. 2006 Aug;131(2):461-9.

PMID:
16890600
14.

Hepatic arterial infusion chemoembolization therapy for advanced hepatocellular carcinoma: multicenter phase II study.

Nagamatsu H, Sumie S, Niizeki T, Tajiri N, Iwamoto H, Aino H, Nakano M, Shimose S, Satani M, Okamura S, Kuromatsu R, Matsugaki S, Kurogi J, Kajiwara M, Koga H, Torimura T.

Cancer Chemother Pharmacol. 2016 Feb;77(2):243-50. doi: 10.1007/s00280-015-2892-7. Epub 2016 Jan 11.

PMID:
26754678
15.

Prospective and randomized trial of lipiodol-transcatheter arterial chemoembolization for treatment of hepatocellular carcinoma: a comparison of epirubicin and doxorubicin (second cooperative study). The Cooperative Study Group for Liver Cancer Treatment of Japan.

Kawai S, Tani M, Okamura J, Ogawa M, Ohashi Y, Monden M, Hayashi S, Inoue J, Kawarada Y, Kusano M, Kubo Y, Kuroda C, Sakata Y, Shimamura Y, Jinno K, Takahashi A, Takayasu K, Tamura K, Nagasue N, Nakanishi Y, Makino M, Masuzawa M, Yumoto Y, Mori T, Oda T.

Semin Oncol. 1997 Apr;24(2 Suppl 6):S6-38-S6-45.

PMID:
9151915
16.

Combined transcatheter arterial chemoembolization and local radiotherapy of unresectable hepatocellular carcinoma.

Seong J, Keum KC, Han KH, Lee DY, Lee JT, Chon CY, Moon YM, Suh CO, Kim GE.

Int J Radiat Oncol Biol Phys. 1999 Jan 15;43(2):393-7.

PMID:
10030267
17.

Phase I/II multicenter study of transarterial chemoembolization with a cisplatin fine powder and porous gelatin particles for unresectable hepatocellular carcinoma: Japan Interventional Radiology in Oncology Study Group Study 0401.

Osuga K, Arai Y, Anai H, Takeuchi Y, Aramaki T, Sugihara E, Yamamoto T, Inaba Y, Ganaha F, Seki H, Sadaoka S, Sato M, Kobayashi T, Kodama Y, Inoh S, Yamakado K.

J Vasc Interv Radiol. 2012 Oct;23(10):1278-85. doi: 10.1016/j.jvir.2012.06.028. Epub 2012 Aug 24.

PMID:
22922041
18.

Conventional versus doxorubicin-eluting bead transarterial chemoembolization for hepatocellular carcinoma.

Sacco R, Bargellini I, Bertini M, Bozzi E, Romano A, Petruzzi P, Tumino E, Ginanni B, Federici G, Cioni R, Metrangolo S, Bertoni M, Bresci G, Parisi G, Altomare E, Capria A, Bartolozzi C.

J Vasc Interv Radiol. 2011 Nov;22(11):1545-52. doi: 10.1016/j.jvir.2011.07.002. Epub 2011 Aug 16.

PMID:
21849247
19.

Lipiodol trans-arterial chemoembolization of hepatocellular carcinoma with idarubicin: first experience.

Favelier S, Boulin M, Hamza S, Cercueil JP, Cherblanc V, Lepage C, Hillon P, Chauffert B, Krausé D, Guiu B.

Cardiovasc Intervent Radiol. 2013 Aug;36(4):1039-46. doi: 10.1007/s00270-012-0532-8. Epub 2012 Dec 8.

PMID:
23224215
20.

Chemoembolization of unresectable hepatocellular carcinoma: Decreased toxicity with slow-release doxorubicin‑eluting beads compared with lipiodol.

Recchia F, Passalacqua G, Filauri P, Doddi M, Boscarato P, Candeloro G, Necozione S, Desideri G, Rea S.

Oncol Rep. 2012 May;27(5):1377-83. doi: 10.3892/or.2012.1651. Epub 2012 Jan 25.

PMID:
22294036
Items per page

Supplemental Content

Write to the Help Desk